About the Researcher

Gary S. Goldman holds a Ph.D. in Computer Science from Pacific Western University in Los Angeles and graduated with honors in 1977 from California State University, Fullerton (CSUF) with a double major: B.S. Engineering (Electronic emphasis) and B.S. Computer Science. He was elected member of the Phi-Kappa-Phi honor society and in 1976 received the Outstanding University Engineering Student Award, presented by the Orange County Engineering Education Council (OCEC). At graduation he received a special Merit Award in recognition of scholarly commitment and outstanding Academic Achievement in Computer Science, presented by CSUF.

At CSUF, Goldman was employed as a computer consultant assisting faculty and staff. He later served as a part-time assistant professor for the Engineering and Quantitative Methods departments instructing both graduate and undergraduate courses in statistics, programming, digital simulation, and digital logic design and switching theory.

Patented "Power Wheel"

In 1980, as vice-president of Systems Development of Cascade Graphics Development, he developed the first microcomputer-based computer-aided drafting (CAD) system (prior to the well known AutoCad product; see figure). This system used an Apple II to process user inputs and a 68000 microprocessor to perform real time graphics. Dr. Gilbert McCann, then professor emeritus of CalTech, served on the board of directors of this company. Goldman engaged in computer consulting tours to South Africa, Germany, Holland, England and Canada. Goldman holds a U.S. patent (#4223255, granted September, 1980) for a micro-programmed, high-efficiency motor-in-a-wheel called “Power Wheel,” for use in electric vehicular applications. This invention was featured on the front cover of the Fall, 1980 issue of Science and Mechanics (see figure).

Goldman, V.P. Cascade Graphics Dev.,
with First CAD System in 1980.

After operating one year independently, Cascade Graphics Development was acquired by an international petrochemical company. In the early 1980’s, Dr. Goldman assisted with the integration of the graphics system and voice input Technology. This product, unique for its time, permitted disabled persons to be productive and generate high quality drawings. He recalls hiring a quadriplegic who accomplished fulfilling and productive work on this system. Dr. Goldman automated the design of vertical cylindrical heaters, including convection coil design and tube-wall thickness calculations for the piping. Dr. Goldman wrote a heuristic program that designed earth retaining walls with and without traffic loads and provided the complete materials list and drawing for the project. Goldman’s program could produce a 100-foot long wall along any given terrain in five minutes—a task that previously took several engineers an entire week to accomplish. He also developed a specialized curve fitting routine, used by pilot Burt Rutan, suitable for aircraft wing design.

Gary S. Goldman, Vice-President
Cascade Graphics Development

He co-developed the Goldman/Blake remediation program for children with specific visual process deficits; this program was used in a pilot study at the Hope-Haven Hospital in Florida. In 1976, he served on a development team that produced the first Interactive Graphics Terminal, IGT-100, at CalComp (California Computer Products, Anaheim, CA) This system allowed drawings to be edited prior to their being electronically plotted.

For 30 plus years, Goldman has served as a computer consultant responsible for the automation of a wide variety of businesses, improved production, and conversion of databases. He has authored and presented numerous manuscripts contributing to engineering and computer science disciplines and enjoys writing heuristic programs (developing algorithms based on ones knowledge and intuition concerning a problem).

Dr. Goldman served for eight years (from January, 1995 until his resignation in October of 2002) as Research Analyst for the Varicella Active Surveillance Project (VASP) in Antelope Valley, in a cooperative project with the Centers for Disease Control and Prevention (CDC, Atlanta, GA). He developed a model that quantified the seasonal variation in chickenpox based on school enrollment (clustering) and high ambient air temperature. Additionally, he created a database and data entry programs for several hundred demographic and clinical variables pertaining to chickenpox and shingles. This included logic to detect case duplicates (important for application of capture-recapture methods) and link cases originating from the same household. He also supplied the initiative and background material for the proposal to add shingles to the active surveillance program. Additionally, he wrote statistical analyses to (a) investigate 2nd varicella infections (later published in peer-reviewed medical journal), (b) study varicella susceptibility (presented at a symposium and published later outside VASP), (c) quantify transmission of varicella in households, (d) determine chickenpox vaccine efficacy by year (published later outside VASP), (e) track outbreaks of chickenpox in schools, (f) perform a cost-benefit analysis of universal varicella vaccination taking into account the closely related herpes zoster epidemiology (published later outside VASP), and (g) perform capture-recapture to measure reporting completeness of chickenpox cases to the surveillance project (published in The Journal of the American Medical Association--JAMA). Finally, Goldman computed both (1) true shingles incidence rate among children with previous histories of chickenpox and (2) true shingles incidence rate among vaccinated children so as to investigate trends in shingles incidence in a community under moderate to widespread varicella vaccination (published later outside VASP).

Presently, Dr. Goldman serves as a consulting computer scientist and is on the board of directors of Pearblossom Private School, Inc. which provides distance education to over 1,500 independent study students each year in grades K through 8 throughout the United States (see www.PearblossomSchool.com). Dr. Goldman also is a licensed and credentialed teacher for 7-12th grade mathematics and provides technology updates and programs for Pearblossom Academy, Inc. which supports high school students in an accredited course of instruction (see www.PearblossomAcademy.com).

From 2004 through 2010 he served as Editor-in-Chief of the peer-reviewed journal, Medical Veritas: The Journal of Medical Truth (see www.MedicalVeritas.com). Through this endeavor Dr. Goldman has had the pleasure of interfacing with world-renowned scientists, researchers, and physicians.

Dr. Goldman has served as a reviewer for the Journal of the American Medical Association (JAMA), Human and Experimental Toxicology (HET), Vaccine, The American Journal of Managed Care (AJMC), Expert Review of Vaccines (ERV), Expert Review of Dermatology (ERD), Journal of the European Academy of Dermatology and Venereology (JEADV), Epidemiology and Infection, The Open Allergy Journal, BioMed Research International (Biomed Res Int), Epidemology & Infection, Therapeutic Advances in Vaccines and Immunotherapy, and British Medical Journal (BMJ). He is included on the Editorial Board of Research and Reviews in BioSciences.

Recent Medical Publications, Abstracts, etc.

[1] Assessing the Impact of Vaccination on the Incidence of Vaccine Preventable Diseases via Harmonic Regression. Presented May 23, 2000 by John W. Glasser (CDC). GS Goldman, JW Glasser, TJ Maupin, CL Peterson, . Mascola, RT Chen, and JF Seward.

[2] The impact of vaccination on varicella incidence, conditional on school attendance and temperature, in Antelope Valley, CA. Goldman GS, Glasser JW, Maupin TJ, Peterson CL, Mascola L, Chen RT, and Seward JF. Presentation by J.W. Glasser at 16th International Conference on Pharmacoepidemiology (ICPE); Barcelona, Spain; August 22, 2000; Pharmacoepidemiology and Drug Safety; 9(Suppl 1):S67.

[3] Varicella active surveillance: use of capture-recapture methods to assess completion of surveillance data. Peterson CL, Maupin T, Goldman G, Mascola L. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 28 - October 1, 1997, Toronto, Canada; Abstract H-111, page 233.

[4] Decline in varicella incidence and hospitalizations in sentinel surveillance areas in the United States, 1995-2000. Seward J, Watson B, Peterson C, Mascola L, Pelosi J, Zhang J, Jumaan A, Maupin T, Goldman G, Perella D, Waites C, Tabony L, Wharton M. The 4th International Conference on VZV, March 3-5, 2001, Oral Presentation, La Jolla, California. VZV Research Foundation in partnership with Columbia University College of Physicians and Surgeons.

[5] Breakthrough varicella cases since vaccine licensure in the Varicella Active Surveillance Project. April 2001 Supplement of Pediatric Research, Presented April 28-May 1, 2001 Pediatric Academic Societies Meeting, Baltimore, Maryland. Galil K, Watson B, Peterson C, Mascola L, Pelosi J, Seward J, Zhang J, Maupin T, Goldman G, Perella D, Waites C, Tabony L, Wharton M. Centers for Disease Control and Prevention, Atlanta, GA; Philadelphia Department of Public Health, Philadelphia, PA; Los Angeles County Department of Health, Los Angeles, CA; Texas Department of Health, Austin, TX; Dyntel Corporation, Atlanta, GA. Publication no. 843.

[6] Knowledge, attitudes, and practices of healthcare providers regarding varicella vaccination in sentinel surveillance area, 1996, 1997, and 1999. Maupin T, Goldman G, Peterson C, Mascola L, Seward J. Poster Session, April 28-May 1 2001, Pediatric Academic Society Annual Meeting, Baltimore, Maryland.

[7] Varicella Epidemiology: six years of active surveillance data following implementation of the varicella vaccination program. Peterson C, Mascola L, Maupin T, Goldman G, Seward J, Presented at the 39th Annual Meeting of the Infectious Diseases Society of America (IDSA), Abstract 943, October 25-28, 2001; San Francisco, California.

[8] Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Xhang JX, Maupin TJ, Goldman GS, Tabony LJ, Brodovicz KG, Jumaan AO, Wharton M. JAMA 2002; 287(5):606–11.

[9] Second varicella infections: are they more common than previously thought? Hall S, Maupin T, Seward J, Jumaan AO, Peterson C, Goldman G, Mascola L, Wharton M. Pediatrics. 2002 Jun;109(6):1068–73.

[10] Varicella susceptibility among adolescents in an active surveillance site. Maupin T, Goldman G, Peterson C, Mascola L, Seward J, Jumaan A, 36th National Immunization Conf. of the CDC, 05/01/02, Denver, CO.

[11] Varicella susceptibility and incidence of herpes-zoster among children and adolescents in a community under active surveillance. Goldman G. Vaccine, 2003 Oct. 1; 21(27-30):4238–42.

[12] Incidence of herpes-zoster among children and adolescents in a community with moderate varicella vaccination coverage. Goldman G. Vaccine, 2003 Oct. 1; 21(27-30):4243–9.

[13] Using capture-recapture methods to assess varicella incidence in a community under active surveillance. Goldman G. Vaccine, 2003 Oct 1; 21(27-30):4250–55.

[14] Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology. Goldman G. Vaccine, 2005 May; 23(25):3349–55.

[15] An investigation of the association between MMR vaccination and autism in Denmark. Goldman G, Yazbak EF, Journal of Association of American Physicians and Surgeons, Fall 2004; 9(3):70–5.

[16] Response to Letter to Editor by Jumaan: Goldman’s role in the Varicella Active Surveillance Project. Goldman GS. Vaccine, 2004 Sep 3; 22(25-26):3232–6. (doi:10.1016/j.vaccine.2004.07.001)

[17] Annual Summary, Each year 1995 through 2001, Antelope Valley Varicella Active Surveillance Project (VASP), Los Angeles County Department of Health Services (LACDHS); Centers for Disease Control and Prevention (CDC) Cooperative Agreement No. U66/CCU911165-10; Maupin T, Goldman G, Peterson C, Mascola L.

[18] Universal varicella vaccination: Efficacy trends and effect on herpes-zoster. Goldman GS. International Journal of Toxicology, 2005 July-Aug.;24(4):205–13.

[19] The Case against Universal Varicella Vaccination. [Commentary] Goldman GS. International Journal of Toxicology, 2006 Sept.-Oct.,25(5):313–17.

[20] Infant mortality rates regressed against number of vaccine doses routinely given: Is there a biochemical or synergistic toxicity? Miller NZ, Goldman GS. Hum Exp Toxicol., 2011 Sept.; 30(9):1420–8. (Sage Open Access article: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170075/pdf/10.1177_0960327111407644.pdf)
Interestingly, developed countries that vaccinated the most had the highest infant mortality rates (IMR). This relationship has since been further investigated by performing an odds ratio analysis with the countries divided at the median IMR and total vaccine doses, then controlling for the following factors for each nation: (1) child poverty rates, (2) low birth weights, (3) pertussis vaccination rates, (4) breast feeding rates, (5) teenage fertility rates, (6) births out of wedlock rates, (7) age at first marriage, (8) percent of divorces with/without children involved, (9) total fertility rates, and (10) pertussis incidence rates. Although child poverty rates, pertussis vaccination rates, and teenage fertility rates were significant predictors of IMR, none of these factors lowered the partial correlation below 0.62, thus, robustly confirming the study's findings.

[21] Relative trends in hospitalizations and mortality among infants by number of vaccine doses and age, based on the Vaccine Adverse Event Reporting System (VAERS), 1990-2010. Goldman GS, Miller NZ. Hum Exp Toxicol 2012 Oct; 31(10):1012–21.

[22] Comparison of VAERS fetal-loss reports during three consecutive influenza seasons: Was there a synergistic fetal toxicity associated with the two-vaccine 2009/10 season? Goldman GS. Hum Exp Toxicol 2012 Oct;31(10):1012–21.
A study using different methodology, but supporting the same conclusion is:
Browna IA, Austinb DW. Maternal transfer of mercury to the developing embryo/fetus: is there a safe level?
Toxicological & Environmental Chemistry 2012 Sept;94(8):1610-27
DOI: 10.1080/02772248.2012.724574
Abstract: Mercury (Hg) exposure is ubiquitous in modern society via vaccines, fish/crustacea, dental amalgam, food, water, and the atmosphere. This article examines Hg exposure in the context of primary exposure to pregnant women and secondary exposure experienced by their unborn babies. Babies in utero are particularly at risk of higher Hg exposure than adults (on a dose/weight basis through maternal Hg transfer via the placenta), and are more susceptible to adverse effects from mercury and its biologically active compounds. It is, therefore, critical that regulatory advisories around maximum safe Hg exposures account for pregnant women and secondary exposure that children in utero experience. This study focused on standardized embryonic and fetal Hg exposures via primary exposure to the pregnant mother of two common Hg sources (dietary fish and parenteral vaccines). Data demonstrated that Hg exposures, particularly during the first trimester of pregnancy, at well-established dose/weight ratios produced severe damage to humans including death. In light of research suggestive of a mercuric risk factor for childhood conditions such as tic disorders, cerebral palsy, and autism, it is essential that Hg advisories account for secondary prenatal human exposures.
Background rates of fetal-loss reports in VAERS, the CDC researchers, attempting to "portray" how safe flu shots given to pregnant women were for those mothers' developing fetuses, published that their studies had determined "what" the background rate for fetal-loss reports to VAERS was over an extended period, which extended from the early 1990s through the end of the 2008-2009 flu season.

From the CDCs data and an examination of the fetal-loss reports to VAERS, the average was about 1 fetal-loss report per flu season with "0" in several of the flu seasons and flu season fetal-loss values in VAERS of at most 4 fetal-loss reports related to the inactivated influenza vaccine only in the most recent flu seasons ending with the 2008-2009 flu season.

A further study from CDC supports the same conclusion:
Vaccine. 2017 Sep 25;35(40):5314-5322. doi: 10.1016/j.vaccine.2017.06.069. Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 2010-11 and 2011-12. Donahue JG, Kieke BA, King JP, DeStefano F, Mascola MA, Irving SA, Cheetham TC, Glanz JM, Jackson LA, Klein NP, Naleway AL, Weintraub E, Belongia EA.
Association of spontaneous abortion with receipt of inactivated influenza vaccine containing H1N1pdm09 in 201011 and 201112
INTRODUCTION: Inactivated influenza vaccine is recommended in any stage of pregnancy, but evidence of safety in early pregnancy is limited, including for vaccines containing A/H1N1pdm2009 (pH1N1) antigen. We sought to determine if receipt of vaccine containing pH1N1 was associated with spontaneous abortion (SAB).
METHODS: We conducted a case-control study over two influenza seasons (2010-11, 2011-12) in the Vaccine Safety Datalink. Cases had SAB and controls had live births or stillbirths and were matched on site, date of last menstrual period, and age. Of 919 potential cases identified using diagnosis codes, 485 were eligible and confirmed by medical record review. Exposure was defined as vaccination with inactivated influenza vaccine before the SAB date; the primary exposure window was the 1-28days before the SAB.
RESULTS: The overall adjusted odds ratio (aOR) was 2.0 (95% CI, 1.1-3.6) for vaccine receipt in the 28-day exposure window; there was no association in other exposure windows. In season-specific analyses, the aOR in the 1-28 days was 3.7 (95% CI 1.4-9.4) in 2010-11 and 1.4 (95% CI 0.6-3.3) in 2011-12. The association was modified by influenza vaccination in the prior season (post hoc analysis). Among women who received pH1N1-containing vaccine in the previous influenza season, the aOR in the 1-28 days was 7.7 (95% CI 2.2-27.3); the aOR was 1.3 (95% CI 0.7-2.7) among women not vaccinated in the previous season. This effect modification was observed in each season.
CONCLUSION: SAB was associated with influenza vaccination in the preceding 28 days. The association was significant only among women vaccinated in the previous influenza season with pH1N1-containing vaccine. This study does not and cannot establish a causal relationship between repeated influenza vaccination and SAB, but further research is warranted.

Since none of the critics have attacked the CDC's published "background-rate" studies or the suitability of using sparsely reported fetal losses in VAERS to support the safety of giving flu shots to pregnant women, it seems that the current critics somehow believe that the use of fetal-loss reports in VAERS, a highly under reported database is somehow a suitable practice for the CDC's estimating vaccination "safety" for the fetus from the "background rate for fetal losses".

In each of these years where there were few or no fetal-loss reports to VAERS, there were also about 4-million plus wanted pregnancies and, presuming 20% end in miscarriages, hundreds of thousands of miscarriages.

Yet the pro-vaccine contingent have no problem with a claim for flu-vaccine "safety" for fetuses based on the highly under reported fetal losses in the VAERS database in the years prior to the 2009-2010 flu season.

However, these self-same naysayers find that it is not suitable for any independent researcher to use the CDC's background rate for fetal-loss reports and the large increase above that background rate in the 2-dose 2009-2010 flu season to show evidence of vaccine- related harm -- a clear double standard.

Against a history of "0 to 4" fetal-loss reports to VAERS in a given flu season that were related to the inactivated influenza vaccine(s) administered, 170+ reports when 2 doses were given in the 2009-2010 flu season followed by "20" such reports in the 2010-2011 flu season when 1 dose of flu vaccine was again given to pregnant women is clearly a "signal" and a value well-above the CDC's published background rate for such fetal-loss reports to VAERS.

[23] Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy primarily based primarily on the Antelope Valley Varicella Active Surveillance Project data. Goldman GS, King PG. Vaccine 2012; 31(13):1680–94; http://dx.doi.org/10.1016/j.vaccine.2012.05.050

[24] Vaccination to prevent varicella: Goldman and King's response to Myers' interpretation of Varicella Active Surveillance Project data. Goldman GS, King P. Hum Exp Toxicol., 2014 Aug. 33(8):886–93. PMID: 24275643.

[25] Insights on the impact of external and internal boosting on varicella-zoster virus reactivation based on evidence from the first decade of the United States universal varicella vaccination program. Goldman GS. Cureus, 2021 Aug. 6; 13(8):e16963. doi:10.7759/cureus.16963

Engineering and CAD Publications

[1] Artificial Intelligence, abstract published and presented at the 4th Annual ACM (Association of Computer Machinery) Computer Science Conference, Feb 12, 1976 Anaheim, CA.

[2] PRISM: An Educational Aide to Symbolic Differentiation and Simplification of Algebraic Expressions, COED (Computers in Education, Division of ASEE), Transactions, Vol. IX, No. 2, 1977, pages 13-32; also presented and published at the WESCON (Western Electric Show and Convention), Los Angeles Convention Center, September 17, 1976.

[3] A FORTRAN IV Implementation for the Numerical Determination and Mohr Diagram Representation of the Triaxial State of Stress at Point, COED (Computers in Education, Division of the American Society of Engineering Education), Application Note No. 42, 1977.

[4] Constructing Stylish Characters on Computer Graphics Systems, Computers in Education Division of ASEE (COED); Vol. XII, No. 11, 1980, pages 111-122.

[5] Computer Aided Design Analysis of Safety Factors Based on Theories of Failure, 1977 Symposium on Application of Computer Methods in Engineering.

[6] IGL (Interactive Graphics Language) Reference Manual, CalComp Systems Division, Manual No. 116e, Nov., 1978.

[7] IGL (Interactive Graphics Language) Procedures Library, CalComp Systems Division, Manual No. 1164, Nov., 1978.

[8] The Power Wheel--Elimination of Energy Consuming Drive Components, presented and published at the IEEE (Institute of Electrical and Electronics Engineers) Region V Annual Conference, “Energy 1978", Tulsa, Oklahoma, April 15-17, 1978; IEEE Cat. No. 78Ch1283-1, pp. 95-99, Tulsa, OK.

[9] Electromotive Torque for Vehicular Applications, presented and published at the 28th IEEE Vehicular Technology Conference, pp. 119-132, March 22-24, 1978; Denver, CO.

[10] Wheel Hub Motors Applied to Electric Vehicle Propulsion, 14th Intersociety Energy Conversion Engineering Conference (IECEC), published by America Chemical Society, Volume 1, pp. 632-636, Aug. 5-10, 1979; Boston, MA

[11] Field Study of the Goldman-Blake Remediation System and Its Effectiveness with Visually Impaired Children, Hope Haven Association/The Florida School for the Deaf and Blind, 1979.

[12] A Heuristic Algorithm for Intersection Cleanup--Implemented in IGL, Copyright 1979, Computers in Education, Division of the American Society for Engineering Education (COED), P.O. Box 308, West Long Branch, NJ 07764; Also published in Proceedings of COMPSAC79, The IEEE Computer Society's Third International Computer Software & Applications Conference, IEEE Catalog No. 79CH1515-6C, pp. 757-762, Nov. 6-8, Chicago, IL.

[13] The Power Wheel, front cover feature in the Fall, 1980 issue of the journal Science and Mechanics.

[14] MDAS: Mechanical Design Application Software, Copyright ©1981 by Cascade Graphics Development.

[15] A New Era In Computer Aided Drafting, Copyright ©1982 by Cascade Graphics Development.

[16] PGL: Pascal Graphics Library, Programmer's Guide, Copyright ©1983 by Cascade Graphics Development.

[17] Cascade V/X Reference Manual, Copyright ©1984 Cascade Graphics Development; User's Manual complete with glossary, description of graphics tasks, and tutorial.

[18] ASAP: Architectural Software Application Package, Copyright ©1984 by Cascade Graphics Development.

[19] Micro-based CAD: A production Tool for Manufacturing Engineering, Computer Graphics Applications for Management and Productivity (CAMP 1984), West Berlin, Germany, Sept. 25-26, 1984, pp. 1-22; Also, Microprocessor Seminar Proceedings of the American Production and Inventory Control Society (APICS), Jan. 30-Feb. 1, 1984, Palm Springs, CA, pp. 74-83.